- Healthcare Professionals
- Research and insights
- Publications
- Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
2018-11-22T00:00:00.000+08:00
Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
https://pubmed.ncbi.nlm.nih.gov/30473431/
Theranostics
Written by
Heck M; Tauber R; Schwaiger S et al.;
Heck M; Tauber R; Schwaiger S et al.;:::